神經退化性疾病市場規模、佔有率、成長分析（按藥物類別、適應症、給藥途徑、最終用戶和地區）- 產業預測，2025 年至 2032 年

2023 年全球神經退化性疾病市場規模價值 526 億美元，預計將從 2024 年的 563.9 億美元成長到 2032 年的 983.4 億美元，預測期內（2025-2032 年）的複合年成長率為 7.2%。

在診斷和治療技術的進步、政府資金的增加以及患者人口結構變化的推動下，全球神經退化性疾病市場正在經歷顯著成長。創新的醫療基礎設施和有針對性的研究計劃正受到關注，特別是針對老年失智症、帕金森氏症和肌萎縮側索硬化症等疾病。透過整合人工智慧和機器學習技術來分析腦部掃描、識別病情進展和定製藥物反應，提高治療效果和診斷準確性正在重塑產業。先進醫療平台的出現支援即時遠端監控和患者與神經科之間的無縫資料交換，從而促進及時干預。此外，對永續性和成本效益的關注正在推動可攜式節能診斷工具的設計。

目錄

介紹

• 調查目的
• 研究範圍
• 定義

調查方法

• 資訊採購
• 二次資料和一次資料方法
• 市場規模預測
• 市場假設與限制

執行摘要

• 全球市場展望
• 供需趨勢分析
• 細分機會分析

市場動態與展望

• 市場概覽
• 市場規模
• 市場動態
  • 促進因素和機會
  • 限制與挑戰
• 波特的分析

關鍵市場考察

• 關鍵成功因素
• 競爭程度
• 主要投資機會
• 市場生態系統
• 市場吸引力指數（2024年）
• PESTEL分析
• 總體經濟指標
• 價值鏈分析
• 定價分析
• 案例研究
• 顧客購買行為分析

神經退化性疾病市場規模（依藥物類別和複合年成長率） (2025-2032)

• 市場概覽
• 免疫調節劑
• 干擾素
• 脫羧酶抑制劑
• 促效劑
• 其他

神經退化性疾病市場規模（按適應症和複合年成長率）（2025-2032）

• 市場概覽
• 多發性硬化症
• 帕金森氏症
• 阿茲海默症
• 脊髓性肌肉萎縮症（SMA）
• 其他

神經退化性疾病市場規模（依給藥途徑及複合年成長率）（2025-2032）

• 市場概覽
• 口服
• 注射
• 經皮

神經退化性疾病市場規模（按最終用戶和複合年成長率） (2025-2032)

• 市場概覽
• 醫院藥房
• 零售藥局
• 網路藥局

神經退化性疾病市場規模（按地區）及複合年成長率（2025-2032）

• 北美洲
  • 美國
  • 加拿大
• 歐洲
  • 德國
  • 西班牙
  • 法國
  • 英國
  • 義大利
  • 其他歐洲國家
• 亞太地區
  • 中國
  • 印度
  • 日本
  • 韓國
  • 其他亞太地區
• 拉丁美洲
  • 巴西
  • 其他拉丁美洲
• 中東和非洲
  • 海灣合作理事會國家
  • 南非
  • 其他中東和非洲地區

競爭資訊

• 前五大公司對比
• 主要企業市場定位（2024年）
• 主要市場參與者所採取的策略
• 近期市場趨勢
• 公司市場佔有率分析（2024年）
• 主要企業簡介
  • 公司詳情
  • 產品系列分析
  • 公司分部佔有率分析
  • 收益同比對比（2022-2024 年）

主要企業簡介

• Biogen
• Pfizer, Inc.
• Hoffmann-La Roche Ltd
• Merck & Co., Inc.
• Novartis AG
• Teva Pharmaceutical Industries Ltd.
• Orion Pharma
• UCB SA
• ACADIA Pharmaceuticals Inc.
• Lundbeck A/S

結論和建議

Global Neurodegenerative Disease Market size was valued at USD 52.6 billion in 2023 and is poised to grow from USD 56.39 billion in 2024 to USD 98.34 billion by 2032, growing at a CAGR of 7.2% during the forecast period (2025-2032).

The global neurodegenerative disease market is experiencing significant growth, propelled by advancements in diagnostic and treatment technologies, increased government funding, and evolving patient demographics. Innovative healthcare infrastructures and targeted research initiatives are gaining prominence, particularly for conditions such as Alzheimer's, Parkinson's, and ALS. Enhancements in treatment efficacy and diagnostic accuracy are reshaping the industry, with the integration of AI and machine learning techniques to analyze brain scans, identify disease progression, and tailor medication responses. The emergence of advanced medical platforms supports real-time remote monitoring and seamless data exchange between patients and neurologists, facilitating timely interventions. Furthermore, a focus on sustainability and cost-efficiency is driving the design of portable, energy-efficient diagnostic tools, ensuring greater accessibility in underserved areas while enabling continuous patient evaluation.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Neurodegenerative Disease market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Neurodegenerative Disease Market Segments Analysis

Global Neurodegenerative Disease Market is segmented by Drug Class, Disease Indication, Route of Administration, End User and region. Based on Drug Class, the market is segmented into Immunomodulator, Interferons, Decarboxylase Inhibitors, Dopamine Agonists and Others. Based on Disease Indication, the market is segmented into Multiple Sclerosis, Parkinson's Disease, Alzheimer's Disease, Spinal Muscular Atrophy (SMA) and Others. Based on Route of Administration, the market is segmented into Oral, Injection and Transdermal. Based on End User, the market is segmented into Hospital Pharmacy, Retail Pharmacy and Online Pharmacy. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Neurodegenerative Disease Market

Advancements in diagnostic technologies such as PET scans, biomarker-focused blood tests, and AI-driven neuroimaging have significantly improved the early and accurate identification of neurodegenerative diseases. These innovations enhance patient management and treatment outcomes through timely detection. Consequently, the global market is experiencing growth across diagnostic, therapeutic, and monitoring sectors, driven by these developments. This surge is further fostering an increase in clinical trials and research investments, as the focus on effective solutions for neurodegenerative conditions intensifies. As a result, the landscape of the neurodegenerative disease market is evolving, reflecting the urgent need for improved therapies and diagnostics.

Restraints in the Global Neurodegenerative Disease Market

The Global Neurodegenerative Disease market faces significant challenges due to the high costs associated with advanced therapies, which often include expensive medications, continuous care, and specialized diagnostic tools. These financial barriers particularly affect patients in low- and middle-income countries, limiting their access to innovative treatments such as gene therapy and monoclonal antibodies. The burden of substantial out-of-pocket expenses hampers the adoption of these therapies, leading to delays in early intervention. Consequently, this situation adversely affects the long-term health outcomes for patients across various regions, exacerbating the existing disparities in healthcare accessibility and treatment effectiveness.

Market Trends of the Global Neurodegenerative Disease Market

The global neurodegenerative disease market is witnessing a significant trend driven by the integration of artificial intelligence (AI) in diagnostics. This technological advancement enables early detection of conditions like Alzheimer's by analyzing patient histories, blood biomarkers, and brain scans with remarkable precision. As AI algorithms enhance diagnosis speed and clinical accuracy, healthcare providers are increasingly adopting these tools, resulting in a more proactive approach to neurodegenerative disease management. This shift not only facilitates timely interventions but also fosters improved patient outcomes, thereby solidifying AI's role as a pivotal catalyst for growth in the neurodegenerative diseases market.

Table of Contents

Introduction

• Objectives of the Study
• Scope of the Report
• Definitions

Research Methodology

• Information Procurement
• Secondary & Primary Data Methods
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Supply & Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Overview
• Market Size
• Market Dynamics
  • Drivers & Opportunities
  • Restraints & Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of substitute
  • Bargaining power of buyers
  • Threat of new entrants
  • Bargaining power of suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Top Investment Pockets
• Market Ecosystem
• Market Attractiveness Index, 2024
• PESTEL Analysis
• Macro-Economic Indicators
• Value Chain Analysis
• Pricing Analysis
• Case Studies
• Customer Buying Behavior Analysis

Global Neurodegenerative Disease Market Size by Drug Class & CAGR (2025-2032)

• Market Overview
• Immunomodulator
• Interferons
• Decarboxylase Inhibitors
• Dopamine Agonists
• Others

Global Neurodegenerative Disease Market Size by Disease Indication & CAGR (2025-2032)

• Market Overview
• Multiple Sclerosis
• Parkinson's Disease
• Alzheimer's Disease
• Spinal Muscular Atrophy (SMA)
• Others

Global Neurodegenerative Disease Market Size by Route of Administration & CAGR (2025-2032)

• Market Overview
• Oral
• Injection
• Transdermal

Global Neurodegenerative Disease Market Size by End User & CAGR (2025-2032)

• Market Overview
• Hospital Pharmacy
• Retail Pharmacy
• Online Pharmacy

Global Neurodegenerative Disease Market Size & CAGR (2025-2032)

• North America (Drug Class, Disease Indication, Route of Administration, End User)
  • US
  • Canada
• Europe (Drug Class, Disease Indication, Route of Administration, End User)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Drug Class, Disease Indication, Route of Administration, End User)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Drug Class, Disease Indication, Route of Administration, End User)
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Drug Class, Disease Indication, Route of Administration, End User)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2024
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2024
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2022-2024)

Key Company Profiles

• Biogen
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Pfizer, Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Hoffmann-La Roche Ltd
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Merck & Co., Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Novartis AG
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Teva Pharmaceutical Industries Ltd.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Orion Pharma
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• UCB S.A
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• ACADIA Pharmaceuticals Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Lundbeck A/S
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations